Promore Pharma has enrolled first patient in HEAL LL-37 in Poland
STOCKHOLM, 1 October 2018 -- Promore Pharma AB, a Swedish biopharmaceutical developer of therapeutic peptides, today announced that the first patient has been enrolled in the company’s Phase II-study (HEAL) with the company’s product candidate LL-37 for treatment of venous leg ulcers. The patient is treated at Klinika Flebologii in Warsaw.Promore Pharma’s phase IIb study with LL-37, HEAL (A Study in Patients with Hard-to-Heal Venous Leg Ulcers to Measure Efficacy and Safety of Locally Administered LL-37) is anticipated to recruit 120 patients in Sweden and Poland with venous leg ulcers (VLU)